(MENAFN- GlobeNewsWire - Nasdaq) Partnership Combines VERAXA's Proprietary ADC Technology with OmniAb's Antibody Discovery Technology for Novel Therapies Targeting Solid Tumors ZURICH, SWITZERLAND ...

The objective response rate across dose levels was 41.4%. A TROP2-directed antibody-drug conjugate, DB-1305/BNT325, demonstrated durable activity in patients with previously treated ovarian cancer ...

AI technology has emerged as a game changer in advanced bio research. Using AI reduces the time and expense of drug development, and personalized precision medicine has also become possible.

The approval made UCB’s drug the first for gMG approved to treat both AChR and MuSK antibody-positive patients. UCB has also won approval for a second gMG drug dubbed Zilbrysq, which blocks the ...

The Food and Drug Administration on Wednesday approved an antibody drug that developer Johnson & Johnson expects will eventually become one of its top-selling medicines. The drug, which J&J will sell ...

The poster is available on Innate Pharma’s website. IPH4502 is a differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) conjugated to exatecan targeting Nectin-4, a cell adhesion ...

its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4. The data were presented at the American Association for Cancer Research (AACR) Annual ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

Enhertu (trastuzumab deruxtecan) is an antibody-drug conjugate, a new class of drug that is designed to more precisely target and kill cancer cells than standard chemotherapy. The trial to test ...